Clinical Pharmacology and Translational Medicine (CPTM)
Online ISSN: 2572-7656
NLM ID: 101718870
Segura Aguilar Juan Ernesto (Editor-in-Chief), University of Chile
“Translational research requires the involvement of two separate scientific areas such as basic and clinical research. Unfortunately, the active collaboration between clinicians and basic scientist do not work very well. Basic scientists are deeply involved in the mechanism of a disease but have a large ignorance of clinical aspects of the disease while clinicians are deeply involved in symptoms and disease progression but with low understand of basic mechanisms of the disease. A more active collaboration between basic and clinician scientists is required to face a disease cure or developing new therapies. Another important problem is the huge increase in the information. The scientific information grows both in amplitude and also in depth that make difficult for scientist to digest all the information, increasing the gap between basic and clinician scientists”- Segura Aguilar Juan Ernesto Ph. D. Editor-in-Chief, Clinical Pharmacology and Translational Medicine (CPTM)
Aims & Scope: Clinical Pharmacology and Translational Medicine is an international, peer-reviewed, open access journal for researchers and clinical communities worldwide who aim to expedite translating the products of basic research into novel diagnostic and therapeutic approaches to patient care.
CPTM journal aims at providing high standard quality articles with reliable, comprehensive, up-to-date and evidence-based information on developing new drugs with translational relevance thus laying emphasis on the better scientific understanding of human health and disease by bridging drug discovery with clinical practice.
CPTM is dedicated to publishing cutting-edge research on identification of promising drug targets in preclinical studies; preclinical and clinical pharmacokinetic /pharmacodynamic studies; safety and efficacy of drugs in humans as well as reports on prognostics, novel insights in biomarker development.
The journal will offer multiple venues to present authors investigations as original research papers, review papers, clinical studies, editorials, perspective papers, commentaries, and letters to the editor covering a broad range of areas such as pharmacogenomics, pharmacometrics, Pharmacoepidemiology, pharmacovigilance, and human pharmacology.
CPTM will publish high-quality research articles, provide novel insights, ask provocative questions and discuss new hypothesis in this emerging field. We hope that strong criteria for the peer-review process, transparency of the editorial policy assure the success of translation; and we rely on continuing support of the scientific community in all aspects of the journal’s activity.